A Phase 2, randomized, double-blind, cross-over study of S-600918 in subjects with refractory/unexplained chronic cough

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sivopixant (Primary)
Indications Cough
Focus Adverse reactions; Therapeutic Use
Sponsors Shionogi

Most Recent Events

14 Oct 2021 Primary endpoint of The rate of change in hourly cough frequency during the daytime from the baseline to two weeks after administration of the study agenthas not been met.(Efficacy)Results published in the European Respiratory Journal
14 Oct 2021 Results published in the European Respiratory Journal
20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight